Combining TGF-β inhibitors with other immunotherapies, such as checkpoint inhibitors (e.g., PD-1/PD-L1 and CTLA-4 antibodies), can enhance the overall anti-tumor immune response. This evidence concerns the gene TGFB1 and neoplasm.